& Srinivasan, M
Ruxolitinib Comes With a Black Box Warning The FDA added a black box warning to ruxolitinib, based on data showing that people taking oral JAK inhibitors faced a small increased risk of serious infections, major heart issues, clotting (thrombosis), cancer, and even death
BPC-157: A synthetic peptide that accelerates tendon healing in preclinical models
In practice, a combination of these approaches is used
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide sit at different points on the price map, and the trial programs behind them, STEP (semaglutide, NEJM 2021) and SURMOUNT (tirzepatide, NEJM 2022), describe the compounds rather than any pricing tier
For more skincare and wellness guidance, visit our Health Blog or read more About Fablous Healthcare.